424B3424B3
Jun 24, 2026Final prospectus0001493152-26-029934
All companies
Trade Aim Immunotech Inc
AI
Aim Immunotech Inc
AIMPublicArchived
Public / ArchivedUnited States(NYSE)Best valuation $7.58M1 market
Public listing
Listed· NYSE· Listing market: United StatesListing date
Not available
Offer price
Not available
Shares offered
Not available
Offering proceeds
Not available
Sources: sec-harvest, nasdaq
IPO Calendar · NYSEIPO
AIMPrice
$0.2735
24h
-3.56%
Valuation
$7.58M
24h volume
$1.76M
Type
IPO
Trade Aim Immunotech IncNow trading publicly. Buy via a broker — opens in a new tab.
IPO Calendar · updated 2h ago
Financials
UnprofitableFrom SEC filings, latest FY ending Dec 31, 2025 · CIK 0000946644.
Revenue · -48.24% YoY
$88K
Net income
-$13.96M
Gross margin
—
Cash
$2.99M
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $88K | $170K | $202K | $141K | $135K |
| Operating income | -$11.66M | -$19.77M | -$31.92M | -$19.92M | -$18.84M |
| Net income | -$13.96M | -$17.32M | -$28.96M | -$19.45M | -$19.13M |
| R&D expense | $3.92M | $6.2M | $10.94M | $6.99M | $7.67M |
| Cash & equivalents | $2.99M | $1.7M | $5.44M | $27.05M | $32.09M |
| Total assets | $5.78M | $8.61M | $19.38M | $40.49M | $57.7M |
| Total liabilities | $15.57M | $9.93M | $9.15M | $2.02M | — |
| Shareholders' equity | -$9.78M | -$1.32M | $10.23M | $38.47M | $56.88M |
About Aim Immunotech Inc
AIM ImmunoTech is an immuno-pharma company focused on developing therapeutics for cancers, immune disorders, and viral diseases.
What the company does
- Develops Ampligen, an investigational immuno-modulator based on rintatolimod and designed to activate innate immune pathways.
- Explores clinical applications across oncology, chronic immune conditions, viral disease, and other immune-system indications.
- Relies on clinical research, regulatory progress, intellectual property, and manufacturing readiness to advance its pipeline.
Business profile
AIM ImmunoTech belongs to the biotechnology market, where evidence from clinical studies, regulatory pathways, capital needs, and partnering opportunities define long-term potential.
SEC IPO filings
Final prospectusEDGAR filings resolved from AIM / CIK 0000946644.
Jun 23, 2026Effective9999999995-26-002094
CORRESPfilename1.htm
Jun 18, 2026SEC correspondence0001493152-26-029405
UPLOADfilename1.pdf
Jun 18, 2026SEC correspondence0000000000-26-006143
424B3424B3
Jun 18, 2026Final prospectus0001493152-26-029325
S-1S-1
Jun 18, 2026Filed0001493152-26-029193
Jun 16, 2026Effective9999999995-26-002022
CORRESPfilename1.htm
Jun 15, 2026SEC correspondence0001493152-26-028704
UPLOADfilename1.pdf
Jun 12, 2026SEC correspondence0000000000-26-005945
S-1S-1
Jun 8, 2026Filed0001493152-26-027714
424B3424B3
Feb 27, 2026Final prospectus0001493152-26-008256
424B4424B4
Feb 17, 2026Final prospectus0001493152-26-006944
Aim Immunotech Inc IPO — frequently asked questions
- When did Aim Immunotech Inc go public?
- Aim Immunotech Inc has already gone public and now trades publicly on NYSE under the ticker AIM.
- Can I buy Aim Immunotech Inc stock?
- Yes — Aim Immunotech Inc is publicly traded on NYSE as AIM. You can follow its live price, valuation and post-IPO performance above.
- What is Aim Immunotech Inc's valuation?
- Aim Immunotech Inc's most recent valuation tracked here is $7.58M, derived from live market prices.